Unicycive Therapeutics (UNCY) Other Operating Expenses (2020 - 2023)

Unicycive Therapeutics has reported Other Operating Expenses for 4 years, with the latest figure at $1.6 million in Q3 2023.

• For the quarter ending Q3 2023, Other Operating Expenses rose 53600.0% year-over-year to $1.6 million; the trailing twelve-month figure through Jun 2024 stood at $1.6 million (up 108.83% YoY), and the FY2021 full-year result was $8.0 million, up 852.56% from the prior year.
• Other Operating Expenses for Q3 2023 stood at $1.6 million, up from $484000.0 in the prior quarter.
• The five-year high for Other Operating Expenses was $6.6 million in Q4 2021, with the low at -$10.4 million in Q1 2023.
• Historically, Other Operating Expenses has averaged -$415636.4 across 4 years, with a median of $484000.0 in 2023.
• Annual changes were most pronounced in 2022 — Other Operating Expenses plunged 225.33% — and 2023, when it jumped 53600.0%.
• Unicycive Therapeutics' Other Operating Expenses stood at $841000.0 in 2020, then surged by 686.8% to $6.6 million in 2021, then sank by 225.33% to -$8.3 million in 2022, then jumped by 119.35% to $1.6 million in 2023.
• The last three Other Operating Expenses figures came in at $1.6 million (Q3 2023), $484000.0 (Q2 2023), and -$10.4 million (Q1 2023), per Business Quant data.